Consort Medical plc, has agreed to acquire the entire issued and to be issued share capital of Aesica Pharmaceuticals Limited for £230 million ($373 million). The closing of the transaction, which is expected to occur in November, is conditional on the approval of Consort Medical's shareholders and clearance by the German competition authorities.Consort’s board of directors has approved the proposed acquisition. 

Consort Medical plc is a UK company listed on the London Stock Exchange focused on developing and manufacturing disposable medical devices for drug delivery, including inhaled, nasal and injectables products through its core operating division Bespak.

Aesica is a contract development and manufacturing organization, providing contract development and manufacturing services for finished dose and active pharmaceutical ingredients.  Aesica business was established in 2004.

Source: Aesica Pharmaceuticals